scholarly journals 167P TRIP13 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse

2020 ◽  
Vol 31 ◽  
pp. S76
Author(s):  
Z. Du ◽  
Y. Wang ◽  
Q. Lv
Keyword(s):  
Breast Cancer ◽  
Liver Metastasis ◽  
Prognostic Indicator ◽  
Metastatic Relapse ◽  
Poor Prognostic Indicator

scholarly journals PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse

Tumor Biology ◽  
2017 ◽  
Vol 39 (7) ◽  
pp. 101042831771349 ◽  
Author(s):  
Jing Yang ◽  
Ning-Ni Wu ◽  
De-Jia Huang ◽  
Yao-Chang Luo ◽  
Jun-Zhen Huang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Metastasis ◽  
Prognostic Indicator ◽  
Metastatic Relapse ◽  
Poor Prognostic Indicator

scholarly journals Neuroendocrine Differentiation in Breast Cancer: Clinicopathological Significance of Bcl-2 Positive Solid Papillary Carcinoma

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Yoichiro Okubo ◽  
Takuji Okubo ◽  
Yoshimi Okubo ◽  
Takao Ishiwatari
Keyword(s):  
Breast Cancer ◽  
Papillary Carcinoma ◽  
Neuroendocrine Tumors ◽  
Ductal Carcinoma ◽  
Neuroendocrine Differentiation ◽  
Prognostic Indicator ◽  
Low Grade ◽  
Term Survival ◽  
Solid Papillary Carcinoma ◽  
Poor Prognostic Indicator

Solid papillary carcinoma (SPC) is considered a rare malignant breast tumor. Maluf and Koerner first reported this disease entity as a special type of ductal carcinoma in situ with several characteristic histopathological features, including low-grade cellular atypia, intracellular or extracellular mucin deposition, and solid papillary growth pattern, as well as neuroendocrine differentiation. The present paper describes a case of SPC with bcl-2 expression, which is known as a marker for malignancy of neuroendocrine tumors. Interestingly, despite bcl-2 expression being a poor prognostic indicator of neuroendocrine tumors, the patient with this tumor has achieved long-term survival (approximately 6 years) at the time of writing this report. Because previous investigators reported that bcl-2 expression might play a role in the inhibition of the development of breast cancer, we suggest that bcl-2 expression might reflect a good prognosis in patients with SPC, rather than being a poor prognostic indicator, as it is in several types of neuroendocrine tumor. However, to confirm this hypothesis, further investigation is required.

scholarly journals SF3B1 mutation is a poor prognostic indicator in luminal B and progesterone receptor-negative breast cancer patients

Oncotarget ◽  
2017 ◽  
Vol 8 (70) ◽  
pp. 115018-115027 ◽  
Author(s):  
Xing Fu ◽  
Ming Tian ◽  
Jia Gu ◽  
Teng Cheng ◽  
Ding Ma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Progesterone Receptor ◽  
Cancer Patients ◽  
Prognostic Indicator ◽  
Breast Cancer Patients ◽  
Luminal B ◽  
Poor Prognostic Indicator

scholarly journals Triple Negative Status is a Poor Prognostic Indicator in Chinese Women with Breast Cancer: a Ten Year Review

2012 ◽  
Vol 13 (5) ◽  
pp. 2109-2114 ◽  
Author(s):  
K.K. Ma ◽  
Wai Wang Chau ◽  
Connie H.N. Wong ◽  
Kerry Wong ◽  
Nicholas Fung ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative ◽  
Chinese Women ◽  
Prognostic Indicator ◽  
Poor Prognostic Indicator

scholarly journals CD39+PD-1+CD8+ T cells mediate metastatic dormancy in breast cancer

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Paulino Tallón de Lara ◽  
Héctor Castañón ◽  
Marijne Vermeer ◽  
Nicolás Núñez ◽  
Karina Silina ◽  
...  
Keyword(s):  
Breast Cancer ◽  
T Cells ◽  
Human Breast Cancer ◽  
Disease Free Survival ◽  
T Cell Response ◽  
Primary Breast Tumor ◽  
Human Breast ◽  
Primary Tumors ◽  
Metastatic Relapse ◽  
Discrete Population

AbstractSome breast tumors metastasize aggressively whereas others remain dormant for years. The mechanism governing metastatic dormancy remains largely unknown. Through high-parametric single-cell mapping in mice, we identify a discrete population of CD39+PD-1+CD8+ T cells in primary tumors and in dormant metastasis, which is hardly found in aggressively metastasizing tumors. Using blocking antibodies, we find that dormancy depends on TNFα and IFNγ. Immunotherapy reduces the number of dormant cancer cells in the lungs. Adoptive transfer of purified CD39+PD-1+CD8+ T cells prevents metastatic outgrowth. In human breast cancer, the frequency of CD39+PD-1+CD8+ but not total CD8+ T cells correlates with delayed metastatic relapse after resection (disease-free survival), thus underlining the biological relevance of CD39+PD-1+CD8+ T cells for controlling experimental and human breast cancer. Thus, we suggest that a primary breast tumor could prime a systemic, CD39+PD-1+CD8+ T cell response that favors metastatic dormancy in the lungs.

scholarly journals Genomic instability-derived plasma extracellular vesicle-microRNA signature as a minimally invasive predictor of risk and unfavorable prognosis in breast cancer

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Siqi Bao ◽  
Ting Hu ◽  
Jiaqi Liu ◽  
Jianzhong Su ◽  
Jie Sun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Diagnosis ◽  
Minimally Invasive ◽  
Genomic Instability ◽  
Extracellular Vesicles ◽  
Disease Risk ◽  
Prognostic Indicator ◽  
Mirna Regulation ◽  
Mirna Signature ◽  
Operating Characteristics

Abstract Background Breast cancer (BC) is the most frequently diagnosed cancer and the leading cause of cancer-associated deaths in women. Recent studies have indicated that microRNA (miRNA) regulation in genomic instability (GI) is associated with disease risk and clinical outcome. Herein, we aimed to identify the GI-derived miRNA signature in extracellular vesicles (EVs) as a minimally invasive biomarker for early diagnosis and prognostic risk stratification. Experimental design Integrative analysis of miRNA expression and somatic mutation profiles was performed to identify GI-associated miRNAs. Then, we constructed a discovery and validation study with multicenter prospective cohorts. The GI-derived miRNA signature (miGISig) was developed in the TCGA discovery cohort (n = 261), and was subsequently independently validated in internal TCGA validation (n = 261) and GSE22220 (n = 210) cohorts for prognosis prediction, and in GSE73002 (n = 3966), GSE41922 (n = 54), and in-house clinical exosome (n = 30) cohorts for diagnostic performance. Results We identified a GI-derived three miRNA signature (MIR421, MIR128-1 and MIR128-2) in the serum extracellular vesicles of BC patients, which was significantly associated with poor prognosis in all the cohorts tested and remained as an independent prognostic factor using multivariate analyses. When integrated with the clinical characteristics, the composite miRNA-clinical prognostic indicator showed improved prognostic performance. The miGISig also showed high accuracy in differentiating BC from healthy controls with the area under the receiver operating characteristics curve (ROC) with 0.915, 0.794 and 0.772 in GSE73002, GSE41922 and TCGA cohorts, respectively. Furthermore, circulating EVs from BC patients in the in-house cohort harbored elevated levels of miGISig, with effective diagnostic accuracy. Conclusions We report a novel GI-derived three miRNA signature in EVs, as an excellent minimally invasive biomarker for the early diagnosis and unfavorable prognosis in BC.

Sign in / Sign up

Export Citation Format

Share Document